...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical epigenetics. >DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer
【24h】

DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer

机译：DNA启动子甲基化作为胆囊癌的诊断和治疗生物标志物

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gallbladder cancer is an infrequent neoplasia with noticeable geographical variations in its incidence around the world. In Chile, it is the main cause of death owing to cancer in women over 40?years old, with mortality rates up to 16.5 per 100,000 cases. The prognosis is poor with few therapeutic options; in advanced cases there is only a 10% survival at 5?years.Several studies mention the possible role of DNA methylation in gallbladder carcinogenesis. This epigenetic modification affects tumor suppressor genes involved in regulation pathways, cell cycle control, cell adhesion and extracellular matrix degradation, in a sequential and cumulative way. Determining DNA methylation patterns would allow them to be used as biomarkers for the early detection, diagnosis, prognosis and/or therapeutic selection in gallbladder cancer.
机译：胆囊癌是一种罕见的肿瘤，在世界范围内发病率具有明显的地理差异。在智利，这是40岁以上女性死于癌症的主要原因，其死亡率高达100,000例16.5。预后差，几乎没有治疗选择;在晚期病例中，5年生存率仅为10％。数项研究提到了DNA甲基化在胆囊癌发生中的可能作用。这种表观遗传修饰以顺序和累积的方式影响涉及调控途径，细胞周期控制，细胞粘附和细胞外基质降解的肿瘤抑制基因。确定DNA甲基化模式将使其可用作胆囊癌早期检测，诊断，预后和/或治疗选择的生物标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号